**Question:** Tildrakizumab was approved in March 2018 for

A. Treatment of psoriasis
B. Treatment of osteoporosis
C. Treatment of Alzheimer's disease
D. Treatment of type 2 diabetes

**Core Concept:** Tildrakizumab is a monoclonal antibody used in the treatment of specific inflammatory conditions. It belongs to the class of drugs known as interleukin (IL)-17 inhibitors. Interleukins are cytokines, which are signaling proteins that help regulate immune responses. IL-17 cytokines play a role in inflammation, and inhibiting them can help suppress immune system overactivity.

**Why the Correct Answer is Right:** Tildrakizumab was approved for the treatment of psoriasis. Psoriasis is a chronic autoimmune disorder characterized by excessive skin inflammation and rapid skin cell growth. By inhibiting IL-17 cytokines, tildrakizumab helps to reduce inflammation and improve skin lesions in patients with moderate to severe plaque psoriasis.

**Why Each Wrong Option is Incorrect:**

A. Treatment of psoriasis (explained above)
B. Treatment of osteoporosis: Osteoporosis is a condition characterized by low bone mass and increased risk of fractures. It is not related to IL-17 cytokines or psoriasis, making this option incorrect.
C. Treatment of Alzheimer's disease: Alzheimer's disease is a neurodegenerative disorder affecting memory and cognitive function. It is unrelated to IL-17 cytokines or psoriasis, rendering this option incorrect.
D. Treatment of type 2 diabetes: Type 2 diabetes is a chronic condition characterized by insulin resistance and impaired glucose regulation. While psoriasis is a risk factor for type 2 diabetes, tildrakizumab targets psoriasis but not diabetes, making this option incorrect.

**Clinical Pearl:** Tildrakizumab is a valuable therapeutic option for patients with moderate to severe plaque psoriasis. By understanding the role of IL-17 cytokines in psoriasis and the drug's mechanism of action, clinicians can accurately prescribe this medication for its intended purpose.